SUBSCRIBE
SUBSCRIBE

Phase I

Drug Development
Biogen’s Early-Stage Alzheimer’s Data Continues to Impress
ALZ’s researchers continue to see hope in Biogen’s aducanumab.
November 2, 2017
 · 
2 min read
 · 
Alex Keown
Drug Development
Tweaks to bluebird bio’s Gene Therapy Approach May be Working
Bluebird is making forays into the CAR-T immuno-oncology market, although it has yet to bring a product to market.
November 1, 2017
 · 
3 min read
 · 
Mark Terry
Drug Development
FDA Calls BioMarin’s Hemophilia A Drug a Breakthrough
BioMarin announced that the FDA granted its valoctocogene roxaparvovec for Hemophilia A Breakthrough Therapy Designation.
October 26, 2017
 · 
2 min read
 · 
Mark Terry
Drug Development
Despite $9B Setback, Eli Lilly Boldly Moves on With Five New Alzheimer’s Candidates
During a fireside chat at BIO in San Diego earlier this summer, Daniel Skovronsky confirmed Eli Lilly’s commitment to finding an effective therapy for ALZ’s disease.
October 26, 2017
 · 
2 min read
 · 
Alex Keown
Ignyta Stock Booms on Promising Mid-Stage Lung Can
Drug Development
Bay Area’s Global Blood Therapeutics Terminates Lung Disease Program
The company is shuttering its GBT440 program to treat idiopathic pulmonary fibrosis (IPF).
October 23, 2017
 · 
2 min read
 · 
Mark Terry
Drug Development
BioPharm Executive: From the Bench to the Clinic
Alnylam’s victory with Patisiran in familial amyloid polyneuropathy (FAP) is significant for more than just the company and its patients.
October 14, 2017
 · 
1 min read
 · 
Karl Thiel
Drug Development
Biogen’s Alzheimer’s Pipeline Gets Some More Love
October 6, 2017
 · 
1 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Drug Development
Bay Area Acerta Pharma Falsified Early Data on a Cancer Compound, Now in Clinical Trials
October 6, 2017
 · 
2 min read
3 Biotechs That Could be Taken Out This Quarter
Drug Development
Amicus Rockets on Early-Stage Pompe Disease Data
October 4, 2017
 · 
2 min read
Celgene Cuddles Up With Another Cambridge Biotech, This Time to Tackle Autoimmune Diseases
Drug Development
Top 5 Celgene Drugs With Blockbuster Potential
September 28, 2017
 · 
3 min read
Load More
PRESS RELEASES
Drug Development
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
June 28, 2023
 · 
5 min read
Drug Development
Microba Commences Phase I Clinical Trial for IBD Therapeutic
June 27, 2023
 · 
6 min read
Drug Development
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
June 27, 2023
 · 
14 min read
Drug Development
IAVI Starts First-in-Human Phase I Clinical Trial of Single-Dose Sudan Virus Vaccine Candidate
June 27, 2023
 · 
6 min read
Drug Development
AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen
June 27, 2023
 · 
4 min read
Drug Development
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701
June 27, 2023
 · 
6 min read
Drug Development
Freya Biosciences Announces Positive Topline Clinical Trial Results for FB101 in Women with Asymptomatic Vaginal Dysbiosis
June 27, 2023
 · 
2 min read
Drug Development
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
June 27, 2023
 · 
5 min read
Drug Development
Lobe Sciences Initiates Phase 1 Clinical Trial of L-130
June 27, 2023
 · 
5 min read
Drug Development
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
June 27, 2023
 · 
4 min read
Drug Development
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
June 27, 2023
 · 
5 min read
Business
ImmunoGenesis and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Trial of IMGS-001 for Relapsed or Refractory Advanced Solid Tumors
June 27, 2023
 · 
6 min read
Drug Development
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
June 27, 2023
 · 
11 min read
Drug Development
Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families
June 27, 2023
 · 
10 min read
Drug Development
cystetic Medicines Initiates Phase 1 Clinical Trial of a Molecular Prosthetic for Cystic Fibrosis
June 26, 2023
 · 
5 min read
Drug Development
Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R
June 26, 2023
 · 
11 min read
Drug Development
Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors
June 26, 2023
 · 
7 min read
Drug Development
Sernova Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™ at American Diabetes Association 83rd Scientific Sessions
June 26, 2023
 · 
9 min read
Drug Development
Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease
June 26, 2023
 · 
11 min read
Drug Development
CANbridge Reports Positive Preliminary Data in the Omoprubart (CAN106) Phase 1b Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
June 26, 2023
 · 
8 min read
Load More